View Financial HealthStageZero Life Sciences 配当と自社株買い配当金 基準チェック /06StageZero Life Sciences配当金を支払った記録がありません。主要情報n/a配当利回り-15.4%バイバック利回り総株主利回り-15.4%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新更新なしすべての更新を表示Recent updatesお知らせ • May 08StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in fundingStageZero Life Sciences Ltd. announced a private placement transaction of of either, or a combination of: (i) up to CAD 2,000,000 of non-convertible notes bearing an interest rate of between 12 % to 14 per % per annum; or a convertible debt offering up to CAD 800,000 of units; each unit consisting of CAD 1,000 principal amount of unsecured convertible debentures bearing an interest rate of 8 % per annum, and 12,500 common share purchase warrants, provided that the aggregate gross proceeds from the debt offering and the convertible debt offering would not exceed CAD 2,000,000 on a combined basis on May 7, 2025. Each warrant is exercisable for one common share of the issuer. The principal amount of the convertible debentures may be converted by the holders into common shares at a floor conversion price to be determined based on the market price of the issuer's common shares on the Toronto Stock Exchange following recommencement of trading of the issuer's common shares on TSX (as required by applicable TSX policies). Each warrant shall be exercisable to purchase a common share at an exercise price that will be three cents higher than the market price for a period of 18 months. The proposed financing is subject to the approval of the TSX.Board Change • Jul 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 03StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$809k free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$9.1m). Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (CA$5.56m market cap, or US$4.10m). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Revenue is less than US$5m (US$2.9m revenue).Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share (further deteriorated from US$0 in 3Q 2022). Revenue: US$745.5k (down 6.7% from 3Q 2022). Net loss: US$821.9k (loss widened US$776.8k from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.お知らせ • Nov 08StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business, Care Oncology, has added the fourth of a series of new program offerings. Pinky Jimenez-Agrawal, with WellnessScript, will provide mental health support specifically for cancer patients at twice-monthly clinics. The first clinic is Thursday November 9, 2023 and is open to patients globally. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the Care Oncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar and mental health support is the fourth pillar. The Company believes that these additional offerings present an excellent entry point for cancer patients to be introduced to the full Care Oncology program. One in three patients with cancer have challenges with mental health: up to 25% of cancer survivors suffer from depression and up to 45% with anxiety. Supporting individuals on their journey towards recovery as well as offering help to terminally ill patients and their families as they prepare for death, is a key aspect of her work. She runs bimonthly drop-in sessions, and provides psychological support on a 1:1 basis, for the members of a leukaemia charity. As a volunteer therapist for Cruse Bereavement Care, she provides counselling to children and young adults. She's an ACT practitioner and a DBT informed therapist. She uses a combination of therapies and mindfulness-based interventions. Her work helps individuals build on their strengths by helping them learn new skills, expand from their own experience and teach strategies to enable them to cope with their issues and develop better well-being habits. The program will be offered virtually, twice a month. The program is open to anyone, not just Care Oncology patients and with times to allow global participation. Interested individuals can sign up at [1]. Participants will pay directly for each session. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT preventative program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by Oncologists and includes Nurse practitioners and Metabolic Specialists.New Risk • Oct 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$928k free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$8.4m). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (CA$4.32m market cap, or US$3.15m). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (US$3.0m revenue).お知らせ • Oct 21Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business Care Oncology, has added the first of a series of new program offerings. The Source Functional Nutrition group will provide educational sessions, live cooking lessons, bi-weekly drop in Cafe's, 1:1 consultation as well as a library of recipes and videos. The program initiatives Friday, October 27th. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the CareOncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar. "25-80% of cancer patients, depending on their age and the type and stage of thecancer, suffer from mal nutrition. This problem has become much more acute since the COVID pandemic as treatment options were delayed and access curtailed. Chemotherapy patients, especially, rely on Oncology Nutrition to help with physical strength and assistance during treatment. Nutritional screening and evaluation, as well as detailed nutritional guidance, are essential to assist with a good outcome" said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. The Source Functional Nutritional offering provides cancer specific nutritional guidance with group information sessions, cooking lessons and one on one sessions. Diet is key to supporting a patient's ability to manage treatment and retain strength. dietary guidance can differ between cancer type and stage of treatment. TheSource program will show participants how to navigate this with concrete tools and recipes. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. Care Oncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Aristotle®? is processed at the Company's clinical laboratory, StageZero Life Sciences Inc., a CAP accredited and CLIA certified high-complex cancer.Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)Second quarter 2023 results: US$0.003 loss per share (improved from US$0.013 loss in 2Q 2022). Revenue: US$793.3k (down 21% from 2Q 2022). Net loss: US$401.5k (loss narrowed 69% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.Reported Earnings • May 19First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)First quarter 2023 results: US$0.02 loss per share (further deteriorated from US$0.006 loss in 1Q 2022). Revenue: US$778.5k (down 41% from 1Q 2022). Net loss: US$1.81m (loss widened 207% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.お知らせ • May 16StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)Third quarter 2022 results: EPS: US$0 (improved from US$0.033 loss in 3Q 2021). Revenue: US$799.4k (up 17% from 3Q 2021). Net loss: US$45.1k (loss narrowed 98% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Nov 12StageZero Life Sciences Ltd. to Report Q3, 2022 Results on Nov 15, 2022StageZero Life Sciences Ltd. announced that they will report Q3, 2022 results Pre-Market on Nov 15, 2022お知らせ • Aug 19StageZero Life Sciences Ltd. announced that it has received CAD 0.177 million in fundingStageZero Life Sciences Ltd. announced a private placement of units issued for gross proceeds of CAD 177,000 on August 18, 2022. Each unit comprised of a $1,000 unsecured convertible debenture bearing interest at a rate of 8% per annum, having a term of 18 months from the date of issuance and is convertible into common shares at a conversion price of CAD 0.11 per common share and 9090 Common Share purchase warrants. Each Warrant is exercisable into one common share of the company at an exercise price of CAD$0.15 per Common Share for a period of 18 months from the date of issuance of the units. Securities issued pursuant to the transaction are subject to a statutory hold period lasting four months and a day after the issuance of the securities.Reported Earnings • Aug 17Second quarter 2022 earnings released: US$0.01 loss per share (vs US$0.067 profit in 2Q 2021)Second quarter 2022 results: US$0.01 loss per share (down from US$0.067 profit in 2Q 2021). Revenue: US$998.2k (up 147% from 2Q 2021). Net loss: US$1.28m (down 130% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.お知らせ • Aug 13StageZero Life Sciences Ltd. to Report Q2, 2022 Results on Aug 16, 2022StageZero Life Sciences Ltd. announced that they will report Q2, 2022 results Pre-Market on Aug 16, 2022お知らせ • May 28+ 1 more updateStagezero Life Sciences Ltd. Announces Resignation of Matthew Pietras as COOStageZero Life Sciences Ltd. announced the resignation of Matthew Pietras as COO.Reported Earnings • May 18First quarter 2022 earnings released: US$0.01 loss per share (vs US$0.12 loss in 1Q 2021)First quarter 2022 results: US$0.01 loss per share (up from US$0.12 loss in 1Q 2021). Revenue: US$1.32m (down 47% from 1Q 2021). Net loss: US$590.5k (loss narrowed 92% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.お知らせ • May 14StageZero Life Sciences Ltd. to Report Q1, 2022 Results on May 17, 2022StageZero Life Sciences Ltd. announced that they will report Q1, 2022 results Pre-Market on May 17, 2022Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.お知らせ • Apr 16StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022.Reported Earnings • Apr 02Full year 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in FY 2020)Full year 2021 results: US$0.11 loss per share. Revenue: US$5.07m (up 22% from FY 2020). Net loss: US$7.48m (loss widened 9.0% from FY 2020).お知らせ • Apr 01StageZero Life Sciences Ltd. Launches AVRT Program for Patients Living in the United KingdomStageZero Life Sciences Ltd. announced the launch of the AVRT™ program for patients living in the United Kingdom. AVRT is an innovative physician-led program aimed at proactively identifying and managing the early warning signs of cancer and chronic disease. The announcement builds on the availability of the AVRT program in the US, and the Care Oncology Clinic service that is currently available within the UK, Europe, the US, and Canada. Created by the physicians and scientists who developed the COC Protocol, AVRT employs a similar approach by identifying the inflammatory and metabolic pathways that may increase the risk of developing cancer and chronic disease, and facilitating personalized early interventions to reduce the risk of disease onset or progression. The AVRT program includes: Comprehensive digital health evaluations; Proprietary panels of blood tests that measure biomarkers of inflammation and metabolic dysfunction; In-depth initial consultations with expert clinicians in the field of metabolic health; Personalized care plans with actionable insights; and Regular physician interval and follow-up appointments to maintain engagement and track progress. The program is designed to empower users to take control of their health by offering readouts of all their AVRT data, enabling them to track their progress and visualize any benefits of the changes they make in real time, as well as continuous access to curated resources to ensure patients are supported to make consistently positive health choices. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.お知らせ • Mar 31StageZero Life Sciences Ltd. to Report Q4, 2021 Results on Apr 01, 2022StageZero Life Sciences Ltd. announced that they will report Q4, 2021 results Pre-Market on Apr 01, 2022お知らせ • Mar 05StageZero Life Sciences Ltd. announced that it has received CAD 1.87 million in fundingOn March 3, 2022, StageZero Life Sciences Ltd. closed the transaction.お知らせ • Mar 01StageZero Life Sciences Ltd. announced that it expects to receive CAD 1.87 million in fundingStageZero Life Sciences Ltd. entered into a securities purchase agreement with an institutional investor to issue 10,000,000 common shares and warrants to purchase up to an aggregate of 10,000,000 common shares at a purchase price of CAD 0.187 per common share and associated warrant for gross proceeds of CAD 1,870,000 on February 28, 2022. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.2206 per common share for a period of four years following the issuance date. The transaction is expected to close on or about March 2, 2022, subject to satisfaction of customary closing conditions and the approval of the Toronto Stock Exchange. No securities were offered or sold to Canadian residents in connection with the Private Placement.お知らせ • Nov 27StageZero Life Sciences Ltd. announced that it has received CAD 4.200001 million in fundingOn November 26, 2021, StageZero Life Sciences Ltd. closed the transaction.お知らせ • Nov 24+ 1 more updateStageZero Life Sciences Ltd. announced that it expects to receive CAD 4.200001 million in fundingStageZero Life Sciences Ltd. entered into a securities purchase agreement to issue 9,375,002 common shares and warrants to purchase up to an aggregate of 9,375,002 common shares at a purchase price of CAD 0.448 per common share and associated warrant for gross proceeds of CAD 4,200,001 on November 23, 2021. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.56 per common share for a period of four years following the issuance date. No securities were offered or sold to Canadian residents and will be issued to institutional investors. The transaction is expected to close on or about November 26, 2021, subject to satisfaction of customary closing conditions and the approval of the Toronto Stock Exchange.Reported Earnings • Nov 18Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.11 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$684.3k (down 53% from 3Q 2020). Net loss: US$2.22m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.お知らせ • Sep 03StageZero Life Sciences Ltd. (TSX:SZLS) completed the acquisition of All Assets of Health Clinics Limited and Health Clinics USA Corp.StageZero Life Sciences Ltd. (TSX:SZLS) entered into a letter of intent to acquire All Assets of Health Clinics Limited and Health Clinics USA Corp. for approximately $28.7 million on March 31, 2021. StageZero Life Sciences Ltd. (TSX:SZLS) entered into a definitive agreement to acquire All Assets of Health Clinics Limited and Health Clinics USA Corp. for $7.9 million on August 16, 2021. The letter of intent commits the HC Companies to negotiate exclusively with StageZero for 120 days and is binding as to payment terms. The payment terms contemplate that StageZero will issue 15 million common shares to the vendors on the closing of the transaction, with an additional 80 million common shares potentially issuable to the vendors post-closing, contingent upon the achievement of certain performance milestones. As per the definitive agreement signed on August 16, 2021, StageZero will issue 12.4 million common shares, which will be issued on closing of the Acquisition, 2.5 million common shares, contingent upon Clinic Operations Limited obtaining a Care Quality Commission license in the United Kingdom and 8 million common shares contingent upon the achievement of certain milestones and StageZero shareholder approval. In the event the Milestones are achieved, and the StageZero shareholders do not approve of the issuance of the Contingent Shares, StageZero is obligated to pay to Health Clinics Limited in lieu of the Contingent Shares CAD 16 million, payable at a rate of 9.5% out of StageZero’s monthly gross revenues. Completion of the Transaction is subject to a number of conditions, including satisfactory due diligence findings by both parties, the obtaining of necessary approvals, including, in the case of StageZero, approval of the TSX and any required shareholder approval, and the execution of a definitive agreement. The definitive agreement will contain representations, warranties, covenants and conditions customary for the transaction. due to the complexity the companies have agreed to extend the timeframe and exclusivity for its completion to August 14, 2021. StageZero Life Sciences Ltd. (TSX:SZLS) completed the acquisition of All Assets of Health Clinics Limited and Health Clinics USA Corp. on September 2, 2021.Executive Departure • Sep 01Interim Chief Financial Officer Carl Solomon has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 0.1%. On the 28th of August, Carl Solomon left the company after 2.9 in the role. We don't have any record of a personal shareholding under Carl's name. Carl is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.92 years.Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.006 loss in 2Q 2020)Second quarter 2021 results: Revenue: US$404.7k (up US$341.3k from 2Q 2020). Net income: US$4.33m (up US$4.60m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.お知らせ • Jun 03Stagezero Life Sciences Offers Drive-Up, COVID-19 PCR Travel Testing with Results Reported the Same DayStageZero Life Sciences Ltd. announced the opening of a new drive-up COVID-19 testing site at 8751 Park Central Drive in Richmond, VA. While most COVID-19 PCR testing programs can only provide a 1-2 day turnaround for results, StageZero's fast-track, drive-up testing program is ideal for those who need results the same day. International air travel is picking up, but many countries - including Canada, Barbados, Bermuda, Jamaica and others - require travelers, regardless of vaccination status, to provide proof of a negative COVID-19 PCR test prior to departure. Most rapid-result testing options currently available are antigen tests, which are not widely accepted for international travel. StageZero Life Sciences provides fast, convenient COVID-19 PCR test results and clear documentation for travel abroad.Reported Earnings • May 19First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$2.48m (up US$2.47m from 1Q 2020). Net loss: US$7.30m (loss widened 170% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.Reported Earnings • Apr 03Full year 2020 earnings releasedThe company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$4.15m (up US$4.01m from FY 2019). Net loss: US$6.86m (loss widened 97% from FY 2019). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.お知らせ • Mar 05StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021.Is New 90 Day High Low • Feb 17New 90-day high: CA$1.45The company is up 96% from its price of CA$0.74 on 18 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 20% over the same period.分析記事 • Jan 25Imagine Holding StageZero Life Sciences (TSE:SZLS) Shares While The Price Zoomed 465% HigherBuying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...Is New 90 Day High Low • Jan 14New 90-day high: CA$0.92The company is up 7.0% from its price of CA$0.86 on 15 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 6.0% over the same period.Is New 90 Day High Low • Dec 16New 90-day low: CA$0.63The company is down 2.0% from its price of CA$0.64 on 16 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period.お知らせ • Dec 06StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 10.000068 million.StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 10.000068 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,243,700 Price\Range: CAD 0.78 Discount Per Security: CAD 0.0546 Transaction Features: Regulation Sお知らせ • Nov 20StageZero Life Sciences Ltd. to Report Q3, 2020 Results on Nov 18, 2020StageZero Life Sciences Ltd. announced that they will report Q3, 2020 results on Nov 18, 2020お知らせ • Nov 14StageZero Life Sciences Ltd. to Provide Rapid Testing Services for Travelers from U.S. and CanadaStageZero Life Sciences Ltd. announced that it has been selected by the Government of Barbados to provide COVID-19 testing services to travelers visiting Barbados from the U.S. and Canada. StageZero will deploy mobile healthcare professionals to draw nasopharyngeal swabs, ship the samples to the Company's lab, and provide test results within 48 hours or less. Barbados requires travelers to get a COVID-19 PCR test 3 days prior to their arrival. They will honor only COVID-19 PCR tests drawn by nasopharyngeal swab which requires a nurse or phlebotomist versus at home self-collection. Traditional labs have not been able to provide at home testing services or test results to meet this window, until now. StageZero's concierge testing service includes national networks of mobile healthcare professionals in the U.S. and in Canada who can visit travelers' homes to draw the sample and provide results within 24-48 hours of taking the sample. Results are sent to travelers by encrypted email and include a PDF that they can upload to the Barbados Government website and have on hand either in paper or on their mobile device to show at the airport.お知らせ • Oct 10StageZero Life Sciences Ltd. Launches Saliva PCR Testing for the Detection of the SARS-COV-2 VirusStageZero Life Sciences Ltd. announced that it has launched a saliva-based PCR test which is designed for easier collection of patient samples. Since May 2020, StageZero has been offering swab-based PCR tests and serology tests. It has now added saliva tests and will shortly introduce an antigen test and a full viral respiratory panel to its test offering. The saliva-based PCR test will have utility not just in the home collection market, but will allow full testing access to companies and communities in remote areas where COVID testing is more difficult. It is also intended to facilitate and speed up time-sensitive testing where companies and patients are operating in a specified time window, but are working remotely. With a variety of COVID-19 tests in the market the Company believes that a strategy about how and when to use each test is absolutely necessary. Each test has a different intended ideal use: Salvia PCR tests are used to detect the SARS-CoV-2 RNA and will be processed in the Company's lab in Virginia in the same way that the PCR nasopharyngeal tests are done. Antigen testing offers a way to immediately determine if a person showing symptoms is infected with SARS-CoV-2 and may therefore infect others. The tests are generally only indicated for the screening of symptomatic patients. The Respiratory Panel will be a highly accurate PCR-based test for 18 viruses and two respiratory bacteria. It will screen for Influenza A, Influenza B, and RSV, amongst the 18 viruses. Testing for multiple respiratory pathogens will not just rule out SARS-CoV-2 infection, but aid physicians in proper patient diagnosis. The Company will continue to respond to the changing market and tailor its offerings as appropriate.Is New 90 Day High Low • Sep 20New 90-day high: CA$0.87The company is up 55% from its price of CA$0.56 on 22 June 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.お知らせ • Aug 15StageZero Life Sciences Ltd. to Report Q2, 2020 Results on Aug 14, 2020StageZero Life Sciences Ltd. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 14, 2020お知らせ • Jun 30StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 4.632327 million.StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 4.632327 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 66,176,100 Price\Range: CAD 0.07 Discount Per Security: CAD 0.0049決済の安定と成長配当データの取得安定した配当: SZLSの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: SZLSの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場StageZero Life Sciences 配当利回り対市場SZLS 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (SZLS)n/a市場下位25% (CA)1.7%市場トップ25% (CA)5.5%業界平均 (Biotechs)2.4%アナリスト予想 (SZLS) (最長3年)n/a注目すべき配当: SZLSは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: SZLSは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: SZLSの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: SZLSが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YCA 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/10/11 15:33終値2024/07/15 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋StageZero Life Sciences Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。3 アナリスト機関Douglas LoeCantor Fitzgerald Canada CorporationChris ThompsoneResearch CorporationClaude CamiréParadigm Capital, Inc.
お知らせ • May 08StageZero Life Sciences Ltd. announced that it expects to receive CAD 2 million in fundingStageZero Life Sciences Ltd. announced a private placement transaction of of either, or a combination of: (i) up to CAD 2,000,000 of non-convertible notes bearing an interest rate of between 12 % to 14 per % per annum; or a convertible debt offering up to CAD 800,000 of units; each unit consisting of CAD 1,000 principal amount of unsecured convertible debentures bearing an interest rate of 8 % per annum, and 12,500 common share purchase warrants, provided that the aggregate gross proceeds from the debt offering and the convertible debt offering would not exceed CAD 2,000,000 on a combined basis on May 7, 2025. Each warrant is exercisable for one common share of the issuer. The principal amount of the convertible debentures may be converted by the holders into common shares at a floor conversion price to be determined based on the market price of the issuer's common shares on the Toronto Stock Exchange following recommencement of trading of the issuer's common shares on TSX (as required by applicable TSX policies). Each warrant shall be exercisable to purchase a common share at an exercise price that will be three cents higher than the market price for a period of 18 months. The proposed financing is subject to the approval of the TSX.
Board Change • Jul 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 03StageZero Life Sciences Ltd. to Report Q4, 2023 Results on May 31, 2024StageZero Life Sciences Ltd. announced that they will report Q4, 2023 results on May 31, 2024
New Risk • Apr 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$809k free cash flow). Share price has been highly volatile over the past 3 months (18% average weekly change). Negative equity (-US$9.1m). Earnings have declined by 22% per year over the past 5 years. Market cap is less than US$10m (CA$5.56m market cap, or US$4.10m). Minor Risks Shareholders have been diluted in the past year (17% increase in shares outstanding). Revenue is less than US$5m (US$2.9m revenue).
Reported Earnings • Nov 17Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0 in 3Q 2022)Third quarter 2023 results: US$0.01 loss per share (further deteriorated from US$0 in 3Q 2022). Revenue: US$745.5k (down 6.7% from 3Q 2022). Net loss: US$821.9k (loss widened US$776.8k from 3Q 2022). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings.
お知らせ • Nov 08StageZero Life Sciences, Ltd. Clinical Business Introduces Fourth Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business, Care Oncology, has added the fourth of a series of new program offerings. Pinky Jimenez-Agrawal, with WellnessScript, will provide mental health support specifically for cancer patients at twice-monthly clinics. The first clinic is Thursday November 9, 2023 and is open to patients globally. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the Care Oncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar and mental health support is the fourth pillar. The Company believes that these additional offerings present an excellent entry point for cancer patients to be introduced to the full Care Oncology program. One in three patients with cancer have challenges with mental health: up to 25% of cancer survivors suffer from depression and up to 45% with anxiety. Supporting individuals on their journey towards recovery as well as offering help to terminally ill patients and their families as they prepare for death, is a key aspect of her work. She runs bimonthly drop-in sessions, and provides psychological support on a 1:1 basis, for the members of a leukaemia charity. As a volunteer therapist for Cruse Bereavement Care, she provides counselling to children and young adults. She's an ACT practitioner and a DBT informed therapist. She uses a combination of therapies and mindfulness-based interventions. Her work helps individuals build on their strengths by helping them learn new skills, expand from their own experience and teach strategies to enable them to cope with their issues and develop better well-being habits. The program will be offered virtually, twice a month. The program is open to anyone, not just Care Oncology patients and with times to allow global participation. Interested individuals can sign up at [1]. Participants will pay directly for each session. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT preventative program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by Oncologists and includes Nurse practitioners and Metabolic Specialists.
New Risk • Oct 22New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Canadian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$928k free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-US$8.4m). Earnings have declined by 20% per year over the past 5 years. Market cap is less than US$10m (CA$4.32m market cap, or US$3.15m). Minor Risks Shareholders have been diluted in the past year (22% increase in shares outstanding). Revenue is less than US$5m (US$3.0m revenue).
お知らせ • Oct 21Stagezero Life Sciences, Ltd. Clinical Business Introduces Third Pillar to Cancer OfferingsStageZero Life Sciences Ltd. announced that its Clinical Business Care Oncology, has added the first of a series of new program offerings. The Source Functional Nutrition group will provide educational sessions, live cooking lessons, bi-weekly drop in Cafe's, 1:1 consultation as well as a library of recipes and videos. The program initiatives Friday, October 27th. Screening to find cancer early is the first pillar (AristotleTM); adjunctive treatment with the CareOncology Protocol is the second; nutritional guidance tailored to the type and stage of the cancer is the third pillar. "25-80% of cancer patients, depending on their age and the type and stage of thecancer, suffer from mal nutrition. This problem has become much more acute since the COVID pandemic as treatment options were delayed and access curtailed. Chemotherapy patients, especially, rely on Oncology Nutrition to help with physical strength and assistance during treatment. Nutritional screening and evaluation, as well as detailed nutritional guidance, are essential to assist with a good outcome" said James Howard-Tripp, Chairman and CEO of StageZero Life Sciences. The Source Functional Nutritional offering provides cancer specific nutritional guidance with group information sessions, cooking lessons and one on one sessions. Diet is key to supporting a patient's ability to manage treatment and retain strength. dietary guidance can differ between cancer type and stage of treatment. TheSource program will show participants how to navigate this with concrete tools and recipes. Care Oncology offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Care Oncology has been treating cancer patients since 2013 using patented COC Protocol™?. It is an individualized therapeutic approach which seeks to simultaneously target multiple metabolic cancer pathways and is intended for adjunctive administration alongside standard-of-care cancer therapy. The aim is to restrict cancer cell energy supply and use. In addition to the COC Protocol, Care Oncology offers the AVRT program. All of the Care Oncology programs are managed by a multi-disciplinary team that is overseen by an Oncologist and includes Nurse Practitioners and Metabolic Specialists. Care Oncology Clinics also offers AVRT a Physician-Led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Aristotle®? is processed at the Company's clinical laboratory, StageZero Life Sciences Inc., a CAP accredited and CLIA certified high-complex cancer.
Reported Earnings • Aug 16Second quarter 2023 earnings released: US$0.003 loss per share (vs US$0.013 loss in 2Q 2022)Second quarter 2023 results: US$0.003 loss per share (improved from US$0.013 loss in 2Q 2022). Revenue: US$793.3k (down 21% from 2Q 2022). Net loss: US$401.5k (loss narrowed 69% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 4% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
Reported Earnings • May 19First quarter 2023 earnings released: US$0.02 loss per share (vs US$0.006 loss in 1Q 2022)First quarter 2023 results: US$0.02 loss per share (further deteriorated from US$0.006 loss in 1Q 2022). Revenue: US$778.5k (down 41% from 1Q 2022). Net loss: US$1.81m (loss widened 207% from 1Q 2022). Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 56% per year, which means it is performing significantly worse than earnings.
お知らせ • May 16StageZero Life Sciences Ltd. to Report Q1, 2023 Results on May 15, 2023StageZero Life Sciences Ltd. announced that they will report Q1, 2023 results on May 15, 2023
Reported Earnings • Nov 17Third quarter 2022 earnings released: EPS: US$0 (vs US$0.033 loss in 3Q 2021)Third quarter 2022 results: EPS: US$0 (improved from US$0.033 loss in 3Q 2021). Revenue: US$799.4k (up 17% from 3Q 2021). Net loss: US$45.1k (loss narrowed 98% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings.
Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Nov 12StageZero Life Sciences Ltd. to Report Q3, 2022 Results on Nov 15, 2022StageZero Life Sciences Ltd. announced that they will report Q3, 2022 results Pre-Market on Nov 15, 2022
お知らせ • Aug 19StageZero Life Sciences Ltd. announced that it has received CAD 0.177 million in fundingStageZero Life Sciences Ltd. announced a private placement of units issued for gross proceeds of CAD 177,000 on August 18, 2022. Each unit comprised of a $1,000 unsecured convertible debenture bearing interest at a rate of 8% per annum, having a term of 18 months from the date of issuance and is convertible into common shares at a conversion price of CAD 0.11 per common share and 9090 Common Share purchase warrants. Each Warrant is exercisable into one common share of the company at an exercise price of CAD$0.15 per Common Share for a period of 18 months from the date of issuance of the units. Securities issued pursuant to the transaction are subject to a statutory hold period lasting four months and a day after the issuance of the securities.
Reported Earnings • Aug 17Second quarter 2022 earnings released: US$0.01 loss per share (vs US$0.067 profit in 2Q 2021)Second quarter 2022 results: US$0.01 loss per share (down from US$0.067 profit in 2Q 2021). Revenue: US$998.2k (up 147% from 2Q 2021). Net loss: US$1.28m (down 130% from profit in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings.
お知らせ • Aug 13StageZero Life Sciences Ltd. to Report Q2, 2022 Results on Aug 16, 2022StageZero Life Sciences Ltd. announced that they will report Q2, 2022 results Pre-Market on Aug 16, 2022
お知らせ • May 28+ 1 more updateStagezero Life Sciences Ltd. Announces Resignation of Matthew Pietras as COOStageZero Life Sciences Ltd. announced the resignation of Matthew Pietras as COO.
Reported Earnings • May 18First quarter 2022 earnings released: US$0.01 loss per share (vs US$0.12 loss in 1Q 2021)First quarter 2022 results: US$0.01 loss per share (up from US$0.12 loss in 1Q 2021). Revenue: US$1.32m (down 47% from 1Q 2021). Net loss: US$590.5k (loss narrowed 92% from 1Q 2021). Over the last 3 years on average, earnings per share has increased by 38% per year but the company’s share price has fallen by 53% per year, which means it is significantly lagging earnings.
お知らせ • May 14StageZero Life Sciences Ltd. to Report Q1, 2022 Results on May 17, 2022StageZero Life Sciences Ltd. announced that they will report Q1, 2022 results Pre-Market on May 17, 2022
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 9 highly experienced directors. Member of Colorectal Cancer Clinical Advisory Board Larry Cohen was the last director to join the board, commencing their role in 2008. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
お知らせ • Apr 16StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022StageZero Life Sciences Ltd., Annual General Meeting, Jun 28, 2022.
Reported Earnings • Apr 02Full year 2021 earnings released: US$0.11 loss per share (vs US$0.15 loss in FY 2020)Full year 2021 results: US$0.11 loss per share. Revenue: US$5.07m (up 22% from FY 2020). Net loss: US$7.48m (loss widened 9.0% from FY 2020).
お知らせ • Apr 01StageZero Life Sciences Ltd. Launches AVRT Program for Patients Living in the United KingdomStageZero Life Sciences Ltd. announced the launch of the AVRT™ program for patients living in the United Kingdom. AVRT is an innovative physician-led program aimed at proactively identifying and managing the early warning signs of cancer and chronic disease. The announcement builds on the availability of the AVRT program in the US, and the Care Oncology Clinic service that is currently available within the UK, Europe, the US, and Canada. Created by the physicians and scientists who developed the COC Protocol, AVRT employs a similar approach by identifying the inflammatory and metabolic pathways that may increase the risk of developing cancer and chronic disease, and facilitating personalized early interventions to reduce the risk of disease onset or progression. The AVRT program includes: Comprehensive digital health evaluations; Proprietary panels of blood tests that measure biomarkers of inflammation and metabolic dysfunction; In-depth initial consultations with expert clinicians in the field of metabolic health; Personalized care plans with actionable insights; and Regular physician interval and follow-up appointments to maintain engagement and track progress. The program is designed to empower users to take control of their health by offering readouts of all their AVRT data, enabling them to track their progress and visualize any benefits of the changes they make in real time, as well as continuous access to curated resources to ensure patients are supported to make consistently positive health choices. The service is available both in person at premises in Harley Street, London, UK, and remotely via telemedicine.
お知らせ • Mar 31StageZero Life Sciences Ltd. to Report Q4, 2021 Results on Apr 01, 2022StageZero Life Sciences Ltd. announced that they will report Q4, 2021 results Pre-Market on Apr 01, 2022
お知らせ • Mar 05StageZero Life Sciences Ltd. announced that it has received CAD 1.87 million in fundingOn March 3, 2022, StageZero Life Sciences Ltd. closed the transaction.
お知らせ • Mar 01StageZero Life Sciences Ltd. announced that it expects to receive CAD 1.87 million in fundingStageZero Life Sciences Ltd. entered into a securities purchase agreement with an institutional investor to issue 10,000,000 common shares and warrants to purchase up to an aggregate of 10,000,000 common shares at a purchase price of CAD 0.187 per common share and associated warrant for gross proceeds of CAD 1,870,000 on February 28, 2022. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.2206 per common share for a period of four years following the issuance date. The transaction is expected to close on or about March 2, 2022, subject to satisfaction of customary closing conditions and the approval of the Toronto Stock Exchange. No securities were offered or sold to Canadian residents in connection with the Private Placement.
お知らせ • Nov 27StageZero Life Sciences Ltd. announced that it has received CAD 4.200001 million in fundingOn November 26, 2021, StageZero Life Sciences Ltd. closed the transaction.
お知らせ • Nov 24+ 1 more updateStageZero Life Sciences Ltd. announced that it expects to receive CAD 4.200001 million in fundingStageZero Life Sciences Ltd. entered into a securities purchase agreement to issue 9,375,002 common shares and warrants to purchase up to an aggregate of 9,375,002 common shares at a purchase price of CAD 0.448 per common share and associated warrant for gross proceeds of CAD 4,200,001 on November 23, 2021. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.56 per common share for a period of four years following the issuance date. No securities were offered or sold to Canadian residents and will be issued to institutional investors. The transaction is expected to close on or about November 26, 2021, subject to satisfaction of customary closing conditions and the approval of the Toronto Stock Exchange.
Reported Earnings • Nov 18Third quarter 2021 earnings released: US$0.02 loss per share (vs US$0.11 loss in 3Q 2020)The company reported a soft third quarter result with weaker revenues and control over costs, although losses reduced. Third quarter 2021 results: Revenue: US$684.3k (down 53% from 3Q 2020). Net loss: US$2.22m (loss narrowed 52% from 3Q 2020). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings.
お知らせ • Sep 03StageZero Life Sciences Ltd. (TSX:SZLS) completed the acquisition of All Assets of Health Clinics Limited and Health Clinics USA Corp.StageZero Life Sciences Ltd. (TSX:SZLS) entered into a letter of intent to acquire All Assets of Health Clinics Limited and Health Clinics USA Corp. for approximately $28.7 million on March 31, 2021. StageZero Life Sciences Ltd. (TSX:SZLS) entered into a definitive agreement to acquire All Assets of Health Clinics Limited and Health Clinics USA Corp. for $7.9 million on August 16, 2021. The letter of intent commits the HC Companies to negotiate exclusively with StageZero for 120 days and is binding as to payment terms. The payment terms contemplate that StageZero will issue 15 million common shares to the vendors on the closing of the transaction, with an additional 80 million common shares potentially issuable to the vendors post-closing, contingent upon the achievement of certain performance milestones. As per the definitive agreement signed on August 16, 2021, StageZero will issue 12.4 million common shares, which will be issued on closing of the Acquisition, 2.5 million common shares, contingent upon Clinic Operations Limited obtaining a Care Quality Commission license in the United Kingdom and 8 million common shares contingent upon the achievement of certain milestones and StageZero shareholder approval. In the event the Milestones are achieved, and the StageZero shareholders do not approve of the issuance of the Contingent Shares, StageZero is obligated to pay to Health Clinics Limited in lieu of the Contingent Shares CAD 16 million, payable at a rate of 9.5% out of StageZero’s monthly gross revenues. Completion of the Transaction is subject to a number of conditions, including satisfactory due diligence findings by both parties, the obtaining of necessary approvals, including, in the case of StageZero, approval of the TSX and any required shareholder approval, and the execution of a definitive agreement. The definitive agreement will contain representations, warranties, covenants and conditions customary for the transaction. due to the complexity the companies have agreed to extend the timeframe and exclusivity for its completion to August 14, 2021. StageZero Life Sciences Ltd. (TSX:SZLS) completed the acquisition of All Assets of Health Clinics Limited and Health Clinics USA Corp. on September 2, 2021.
Executive Departure • Sep 01Interim Chief Financial Officer Carl Solomon has left the companyDuring their tenure, earnings grew by 20% annually compared to the industry average of 0.1%. On the 28th of August, Carl Solomon left the company after 2.9 in the role. We don't have any record of a personal shareholding under Carl's name. Carl is the only executive to leave the company over the last 12 months. The current median tenure of the management team is 3.92 years.
Reported Earnings • Aug 18Second quarter 2021 earnings released: EPS US$0.05 (vs US$0.006 loss in 2Q 2020)Second quarter 2021 results: Revenue: US$404.7k (up US$341.3k from 2Q 2020). Net income: US$4.33m (up US$4.60m from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
お知らせ • Jun 03Stagezero Life Sciences Offers Drive-Up, COVID-19 PCR Travel Testing with Results Reported the Same DayStageZero Life Sciences Ltd. announced the opening of a new drive-up COVID-19 testing site at 8751 Park Central Drive in Richmond, VA. While most COVID-19 PCR testing programs can only provide a 1-2 day turnaround for results, StageZero's fast-track, drive-up testing program is ideal for those who need results the same day. International air travel is picking up, but many countries - including Canada, Barbados, Bermuda, Jamaica and others - require travelers, regardless of vaccination status, to provide proof of a negative COVID-19 PCR test prior to departure. Most rapid-result testing options currently available are antigen tests, which are not widely accepted for international travel. StageZero Life Sciences provides fast, convenient COVID-19 PCR test results and clear documentation for travel abroad.
Reported Earnings • May 19First quarter 2021 earnings releasedThe company reported a solid first quarter result with improved revenues and control over costs, although losses increased. First quarter 2021 results: Revenue: US$2.48m (up US$2.47m from 1Q 2020). Net loss: US$7.30m (loss widened 170% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
Reported Earnings • Apr 03Full year 2020 earnings releasedThe company reported a solid full year result with improved revenues and control over costs, although losses increased. Full year 2020 results: Revenue: US$4.15m (up US$4.01m from FY 2019). Net loss: US$6.86m (loss widened 97% from FY 2019). Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth.
お知らせ • Mar 05StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021StageZero Life Sciences Ltd., Annual General Meeting, May 17, 2021.
Is New 90 Day High Low • Feb 17New 90-day high: CA$1.45The company is up 96% from its price of CA$0.74 on 18 November 2020. The Canadian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 20% over the same period.
分析記事 • Jan 25Imagine Holding StageZero Life Sciences (TSE:SZLS) Shares While The Price Zoomed 465% HigherBuying shares in the best businesses can build meaningful wealth for you and your family. And we've seen some truly...
Is New 90 Day High Low • Jan 14New 90-day high: CA$0.92The company is up 7.0% from its price of CA$0.86 on 15 October 2020. The Canadian market is up 12% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is up 6.0% over the same period.
Is New 90 Day High Low • Dec 16New 90-day low: CA$0.63The company is down 2.0% from its price of CA$0.64 on 16 September 2020. The Canadian market is up 9.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Biotechs industry, which is down 15% over the same period.
お知らせ • Dec 06StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 10.000068 million.StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 10.000068 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 9,243,700 Price\Range: CAD 0.78 Discount Per Security: CAD 0.0546 Transaction Features: Regulation S
お知らせ • Nov 20StageZero Life Sciences Ltd. to Report Q3, 2020 Results on Nov 18, 2020StageZero Life Sciences Ltd. announced that they will report Q3, 2020 results on Nov 18, 2020
お知らせ • Nov 14StageZero Life Sciences Ltd. to Provide Rapid Testing Services for Travelers from U.S. and CanadaStageZero Life Sciences Ltd. announced that it has been selected by the Government of Barbados to provide COVID-19 testing services to travelers visiting Barbados from the U.S. and Canada. StageZero will deploy mobile healthcare professionals to draw nasopharyngeal swabs, ship the samples to the Company's lab, and provide test results within 48 hours or less. Barbados requires travelers to get a COVID-19 PCR test 3 days prior to their arrival. They will honor only COVID-19 PCR tests drawn by nasopharyngeal swab which requires a nurse or phlebotomist versus at home self-collection. Traditional labs have not been able to provide at home testing services or test results to meet this window, until now. StageZero's concierge testing service includes national networks of mobile healthcare professionals in the U.S. and in Canada who can visit travelers' homes to draw the sample and provide results within 24-48 hours of taking the sample. Results are sent to travelers by encrypted email and include a PDF that they can upload to the Barbados Government website and have on hand either in paper or on their mobile device to show at the airport.
お知らせ • Oct 10StageZero Life Sciences Ltd. Launches Saliva PCR Testing for the Detection of the SARS-COV-2 VirusStageZero Life Sciences Ltd. announced that it has launched a saliva-based PCR test which is designed for easier collection of patient samples. Since May 2020, StageZero has been offering swab-based PCR tests and serology tests. It has now added saliva tests and will shortly introduce an antigen test and a full viral respiratory panel to its test offering. The saliva-based PCR test will have utility not just in the home collection market, but will allow full testing access to companies and communities in remote areas where COVID testing is more difficult. It is also intended to facilitate and speed up time-sensitive testing where companies and patients are operating in a specified time window, but are working remotely. With a variety of COVID-19 tests in the market the Company believes that a strategy about how and when to use each test is absolutely necessary. Each test has a different intended ideal use: Salvia PCR tests are used to detect the SARS-CoV-2 RNA and will be processed in the Company's lab in Virginia in the same way that the PCR nasopharyngeal tests are done. Antigen testing offers a way to immediately determine if a person showing symptoms is infected with SARS-CoV-2 and may therefore infect others. The tests are generally only indicated for the screening of symptomatic patients. The Respiratory Panel will be a highly accurate PCR-based test for 18 viruses and two respiratory bacteria. It will screen for Influenza A, Influenza B, and RSV, amongst the 18 viruses. Testing for multiple respiratory pathogens will not just rule out SARS-CoV-2 infection, but aid physicians in proper patient diagnosis. The Company will continue to respond to the changing market and tailor its offerings as appropriate.
Is New 90 Day High Low • Sep 20New 90-day high: CA$0.87The company is up 55% from its price of CA$0.56 on 22 June 2020. The Canadian market is up 6.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 7.0% over the same period.
お知らせ • Aug 15StageZero Life Sciences Ltd. to Report Q2, 2020 Results on Aug 14, 2020StageZero Life Sciences Ltd. announced that they will report Q2, 2020 results at 5:00 PM, Eastern Standard Time on Aug 14, 2020
お知らせ • Jun 30StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 4.632327 million.StageZero Life Sciences Ltd. has completed a Composite Units Offering in the amount of CAD 4.632327 million. Security Name: Units Security Type: Equity/Derivative Unit Securities Offered: 66,176,100 Price\Range: CAD 0.07 Discount Per Security: CAD 0.0049